Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00135798 · ClinicalTrials.gov registry record · Phase 2
Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation
A Phase 2 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 2
- Development phase
- 79
- Enrollment target
NCT00135798 is a Phase 2 study that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 79 participants.
The verdict
NCT00135798, a Phase 2 study, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 79 participants
- Enrollment target
Study Summary
The purpose of this study is to learn if pre-liver transplant treatment, using peginterferon plus ribavirin, will clear hepatitis C virus (HCV) RNA from the blood in HCV-infected recipients and reduce the risk of recurrent HCV and allograft hepatitis following liver transplant.
Interventions
- DRUG LADR Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2005-09 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00135798
The ClinicalTrials.gov registry entry for NCT00135798 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LADR Treatment is the first listed.
NCT00135798 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00135798 about?
NCT00135798 is a clinical study titled "Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation". The purpose of this study is to learn if pre-liver transplant treatment, using peginterferon plus ribavirin, will clear hepatitis C virus (HCV) RNA from the blood in HCV-infected recipients and reduce the risk of recurrent HCV and allograft hepatitis following liver transplant.
What is the current status of trial NCT00135798?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 79 participants. The study started on 2005-09. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00135798?
The interventions under investigation include: LADR Treatment (DRUG).
Who is sponsoring clinical trial NCT00135798?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.